[go: up one dir, main page]

CN111227045B - Application of dairy product in promoting growth of length of mammal - Google Patents

Application of dairy product in promoting growth of length of mammal Download PDF

Info

Publication number
CN111227045B
CN111227045B CN202010104314.1A CN202010104314A CN111227045B CN 111227045 B CN111227045 B CN 111227045B CN 202010104314 A CN202010104314 A CN 202010104314A CN 111227045 B CN111227045 B CN 111227045B
Authority
CN
China
Prior art keywords
use according
bifidobacterium
powder
weight
dairy product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010104314.1A
Other languages
Chinese (zh)
Other versions
CN111227045A (en
Inventor
李玉珍
石羽杰
刘彪
李威
肖竞舟
叶文慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Publication of CN111227045A publication Critical patent/CN111227045A/en
Application granted granted Critical
Publication of CN111227045B publication Critical patent/CN111227045B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pediatric Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention belongs to the field of food or medicine, and particularly discloses an application of a dairy product in preparing food or medicine for improving or promoting the growth of the body length of mammals; the dairy product comprises: a protein providing material, a fat providing material and bifidobacteria; wherein the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains a-whey protein and beta-casein; the raw material for providing fat at least contains palmitic acid glyceride, and the palmitic acid glyceride contains 15% by weight or more of Sn-2 palmitic acid glyceride; the Bifidobacterium is selected from at least one of Bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and Bifidobacterium infantis. The dairy product of the invention can improve or promote the growth of the body length of mammals.

Description

Application of dairy product in promoting growth of length of mammal
Technical Field
The invention belongs to the field of food or medicine, and particularly relates to an application of a dairy product in promoting the growth of the body length of a mammal.
Background
The growth of human body is not a constant velocity process, and the growth rate of human body varies from birth to adult. Taking Chinese as an example, the body length of a born infant is about 50 cm, the body length increases about 11-12 cm in 3 months, increases about 12-13 cm in 3-12 months, continues to increase about 11-12 cm in 1-2 years, increases about 5-7 cm per year in 2 years to early puberty, and increases about 8-9 cm per year in adolescence. The fastest growing period of life is 2 years ago and adolescence. The critical period of increased length requires an adequate supply of nutrients. The research finds that: water with very low mineral content can cause retarded bone density growth and retarded growth of height in adolescents; in the 0 to 2 year old age, protein restriction leads to lower levels of insulin-like growth factor 1 (IGF-1) in healthy children, both forms of restriction, energy restriction (50% reduction in intake) and protein restriction (reduction of protein from 1.0g/kg to 0.66g/kg body weight per day), result in a significant reduction in the nitrogen balance of children, a decrease in IGF-1 concentration, as well as in the concentration of specific IGF binding proteins, affecting body function, body growth and body composition. There is a need for a method of promoting the growth of an infant or juvenile.
The breast milk fat provides 45-60% of energy for the early growth of infants, and more than 98% of the breast milk fat is triglyceride. The positions of different fatty acids in the breast milk esterified with glycerol are different; wherein unsaturated fatty acids such as linoleic acid and alpha-linolenic acid in the breast milk are more than 1 site and 3 sites of the triglyceride; long chain saturated fatty acids such as palmitic acid in the milk are predominantly in the 2 position and the palmitic acid triglyceride so formed is referred to as Sn-2 palmitic acid triglyceride. In the digestive tract, the lipolytic enzymes of the infant's stomach act primarily on the 1-and 3-ester bonds of triglycerides, so that unsaturated fatty acids are first freed and then degraded and absorbed in the duodenum along with Sn-2 palmitic acid monoglyceride. However, the common infant formula powder contains palm oil, most of long-chain saturated fatty acids of the palm oil are esterified on ester bonds at the 1-position and the 3-position of triglyceride, and the palm oil is easy to combine with calcium ions after hydrolysis to form calcium soap, so that the absorption of fat and mineral substances is reduced, and the calcium soap which is difficult to absorb can also cause hard excrement to cause difficult defecation.
Breast milk is rich in a-lactalbumin, a protein rich in essential amino acids, which is digested to produce a variety of bioactive polypeptides. Researches show that the a-lactalbumin digestion product can inhibit pathogenic bacteria such as escherichia coli, pneumococcus, staphylococcus aureus, candida and the like in vitro.
Beta-casein is a casein molecule with the highest content in breast milk, and a polypeptide fragment generated by digestion has the effect of inhibiting the growth of harmful bacteria.
Probiotics are an important component of the gut microbiota. The definitions of probiotics by the world Food and Agriculture Organization (FAO) and the World Health Organization (WHO) are: live bacteria which can exert an effective effect on the health of the consumer can be ingested in an appropriate amount. The bifidobacterium is one of probiotics, and the currently common bifidobacterium strains comprise bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum, bifidobacterium infantis and the like, and a plurality of novel strains.
Disclosure of Invention
The present invention provides the use of a milk product for improving or promoting the growth of the length of a mammal, such as an infant or adolescent.
The invention relates to the use of a milk product for the preparation of a food or medicament for improving or promoting the growth of a mammal;
the dairy product, comprising: a protein providing material, a fat providing material and bifidobacteria; wherein,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains a-whey protein and beta-casein;
the fat-providing raw material contains at least palmitic acid glyceride, and the palmitic acid glyceride contains 15% or more (for example, 18% or more, 20% or more, 15% to 98%, 15% to 90%, 20% to 80%, 20% to 95%, 30%, 40%, 50%, 60%, 70%) by weight of Sn-2 palmitic acid glyceride;
the Bifidobacterium is selected from at least one of Bifidobacterium lactis, bifidobacterium animalis, bifidobacterium longum, bifidobacterium breve, bifidobacterium adolescentis, bifidobacterium bifidum and Bifidobacterium infantis.
In some embodiments of the invention, the protein-providing raw material is 200 to 1600 parts by weight, such as 400 parts by weight, 700 parts by weight, 800 parts by weight, 900 parts by weight, 1000 parts by weight, 1200 parts by weight, 1500 parts by weight; the fat-providing raw material is 70 to 500 parts by weight, for example, 100 parts by weight, 200 parts by weight, 300 parts by weight, or 400 parts by weight.
In some embodiments of the invention, the weight ratio of the a-lactalbumin, the beta-casein and the Sn-2 glyceryl palmitate in the dairy product is (1-10) to (1-10), such as 1 (1-2) to (1-2), 1 (1-5) to (1-5), (1-4) to 1 (1-5), 1 (1-7) to (1-6), 1.32.
In some embodiments of the invention, the dairy product has a viable count of bifidobacteria of 10 per gram of beta-casein 6 ～10 11 CFU, e.g. 10 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU。
In some embodiments of the invention, the bifidobacteria in the dairy product are selected from the group consisting of bifidobacterium BB12 and bifidobacterium HN019.
In some embodiments of the present invention, the ratio of viable count of bifidobacterium BB12 to bifidobacterium HN019 in the dairy product is (1.
In some embodiments of the invention, the source material providing fat in the dairy product is selected from the group consisting of OPO structural fat, vegetable fat and animal fat.
In some embodiments of the invention, the vegetable oil is selected from the group consisting of sunflower oil, corn oil, rapeseed oil, and soybean oil.
In some embodiments of the invention, the fat providing feedstock comprises OPO structural fat, sunflower oil, corn oil, soybean oil and optionally rapeseed oil.
In some embodiments of the invention, the dairy product further comprises a carbohydrate-providing raw material.
In some embodiments of the invention, the carbohydrate is a carbohydrate commonly used in the art.
In some embodiments of the invention, the carbohydrate-providing source is selected from lactose, sucrose, glucose, starch and dextrin, preferably lactose.
In some embodiments of the invention, the carbohydrate-providing source is 100 to 600 parts by weight, such as 100 parts by weight, 150 parts by weight, 200 parts by weight, 250 parts by weight, 300 parts by weight, 350 parts by weight, 400 parts by weight, 450 parts by weight, 500 parts by weight, 560 parts by weight.
In some embodiments of the invention, the dairy product further comprises at least one selected from the group consisting of vitamins, minerals, dietary fiber, DHA, ARA, phospholipids, and choline chloride.
In some embodiments of the invention, the viable count of bifidobacteria per hundred grams of dairy product is 10 3 ～10 15 CFU, e.g. 10 4 CFU、10 5 CFU、10 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU、10 11 CFU、10 12 CFU、10 13 CFU、10 14 CFU。
In some embodiments of the invention, the dairy product comprises the following raw materials:
Figure BDA0002387976320000041
Figure BDA0002387976320000051
the dairy product contains bifidobacterium BB12 and bifidobacterium HN019, wherein the viable count of the bifidobacterium BB12 is 10 per gram of beta-casein 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU), viable count of Bifidobacterium HN019 is 10 per gram of beta-casein 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU)。
In some embodiments of the invention, the dairy product further comprises vitamins and/or minerals.
In some embodiments of the invention, the vitamin is present in an amount of 1 to 500mg per hundred grams of milk product, e.g. 10mg, 20mg, 50mg, 100mg, 120mg, 150mg.
In some embodiments of the invention, the mineral is present in an amount of 10 to 3000mg, such as 20mg, 40mg, 60mg, 100mg, 200mg, 300mg, 400mg, 500mg, 700mg, 800mg, 1000mg, 1500mg, 2000mg, 2500mg, 3000mg, per hundred grams of the dairy product.
In some embodiments of the invention, the vitamin is selected from the group consisting of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K 1 Vitamin B 1 Vitamin B 2 Vitamin B 6 Vitamin B 12 Niacin, folic acid, pantothenic acid, and biotin.
In some embodiments of the invention, the mineral is selected from the group consisting of sodium, potassium, copper, magnesium, iron, zinc, calcium, phosphorus, iodine, selenium, and derivatives thereof.
Some embodiments of the invention include one or more of the following (a) to (d):
(a) The animal milk and milk powder are respectively derived from at least one mammal selected from cow, sheep, horse, deer and camel;
(b) The whey protein powder is selected from desalted whey protein powder, undesalted whey protein powder and a-whey protein powder;
preferably, the weight of the desalted whey protein powder is 1 to 20 times, for example 2, 5, 7, 9, 10, 12, 14, 15, 17, 19 times, the weight of the undesalted whey protein powder;
preferably, the weight of the undesalted whey protein powder is 0.5-40 times of the weight of the a-whey protein powder, such as 1, 2, 5, 10, 20, 25, 30, 35, 40 times;
(c) The dietary fiber is selected from fructo-oligosaccharide and galacto-oligosaccharide;
preferably, the weight ratio of fructooligosaccharide to galactooligosaccharide is 1 (1 to 6), such as 1;
(d) The phospholipid is soybean phospholipid.
In some embodiments of the invention, the animal milk is selected from the group consisting of raw milk, whole milk, low fat milk, and skim milk.
In some embodiments of the invention, the milk powder is selected from the group consisting of whole milk powder, low-fat milk powder, and skim milk powder, preferably whole milk powder and skim milk powder;
preferably, the weight ratio of the whole milk powder to the skim milk powder is (0.1-12) 1, such as 0.2.
In some embodiments of the invention, the dairy product is prepared by:
(1-1) mixing the raw materials except for bifidobacterium, DHA and ARA to obtain a mixture;
(2-1) homogenizing the mixture to obtain a homogeneous material;
(3) Sterilizing the homogenized material to obtain a sterilized material;
(4) Drying the sterilized material to obtain powder;
(5) And dry-mixing the powder, the bifidobacteria, the DHA and the ARA to obtain the dairy product.
Some embodiments of the invention include one or more of the following 1) to 11):
1) The method also comprises a step (1-2) between the steps (1-1) and (2-1): filtering the mixture to remove impurities, and using the obtained filtered material for homogenization treatment in the step (2-1);
2) In the step (2-1), the temperature of the homogenization treatment is 50 ℃ or higher;
3) In the step (2-1), the pressure of the homogenization treatment is 120bar or more;
4) A step (2-2) is further included between the steps (2-1) and (3): concentrating the homogenized material, and using the obtained concentrate for sterilization treatment in the step (3);
preferably, the dry matter content of the concentrate is between 40% and 60% by weight;
5) In the step (3), the temperature of the sterilization treatment is more than 80 ℃;
6) In the step (3), the time of sterilization treatment is 10-60 seconds;
7) In the step (4), before drying treatment, filtering and removing impurities from the sterilized materials;
8) In the step (4), the sterilized material is firstly introduced into a spray drying tower for primary drying, and then the material obtained by the primary drying is introduced into a fluidized bed for secondary drying to obtain powder;
preferably, the air inlet temperature of the spray drying tower is 150-200 ℃;
preferably, the air exhaust temperature of the spray drying tower is 80-120 ℃;
preferably, the negative pressure of the spray drying tower is-10 to-2 mmWG;
preferably, the sterilizing material is introduced into the spray drying tower by means of a high-pressure pump;
more preferably, the pressure of the high-pressure pump is 140 to 250bar;
9) In the step (5), the dry mixing temperature is 20-35 ℃;
10 In step (5), dry mixing is carried out by means of a fluidized bed;
11 The method further comprises step (6): the dairy product is screened.
In some embodiments of the invention, the dairy product comprises:
Figure BDA0002387976320000071
Figure BDA0002387976320000081
Figure BDA0002387976320000091
the dairy product also comprises bifidobacterium BB12 and bifidobacterium HN019, wherein the viable count of the bifidobacterium BB12 is 10 per gram of beta-casein 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU), viable count of Bifidobacterium HN019 is 10 per gram of beta-casein 6 ～10 11 CFU (e.g. 10) 7 CFU、10 8 CFU、10 9 CFU、10 10 CFU) containing 1 to 500mg (e.g. 10mg, 20mg, 50mg, 100mg, 120mg, 150 mg) of vitamins and 10 to 3000mg (e.g. 20mg, 40mg, 60mg, 100mg, 200mg, 300mg, 400mg, 500mg, 700mg, 800mg, 1000mg, 1500mg, 2000mg, 2500mg, 3000 mg) of minerals per hundred grams of dairy product.
In some embodiments of the invention, the mammal is a human, preferably an infant or adolescent.
In the invention, the dairy product is selected from at least one of sterilized milk, reconstituted milk, yoghourt, yogurt, milk powder, formula milk powder, condensed milk, cheese, casein, whey powder, milk fat and milk-containing beverage, and is preferably (infant) formula milk powder.
In the present invention, unless otherwise specified, wherein:
the term "glyceryl palmitate" refers to fatty acid glycerides to which at least one palmitic acid is attached, and may be selected from mono-, di-and tri-esters, where the glyceryl moieties of the di-and tri-esters may also be attached to other fatty acid moieties.
The term "Sn-2 palmitic acid" refers to palmitic acid attached to the Sn-2 position on a glyceryl portion of a fat.
The term "Sn-2 glyceryl palmitate" refers to fatty acid glycerides with palmitic acid attached to the Sn-2 position of the glyceryl moiety, and may be selected from the group consisting of Sn-2 monoglycerides, sn-2 diglycerides and Sn-2 triglycerides; wherein, any fatty acid can be connected to the Sn-1 position and/or the Sn-3 position on the glyceryl in the Sn-2 palmitic acid diglyceride and the Sn-2 palmitic acid triglyceride, and the fatty acid comprises, but is not limited to, palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, lauric acid, myristic acid, arachic acid, myristoleic acid, palmitoleic acid, rapeseed oleic acid, linoleic acid, linolenic acid and the like.
The term "a-lactalbumin" is a protein extracted from milk, has the characteristics of high nutritional value, easy digestion and absorption, multiple active ingredients and the like, and is one of high-quality protein supplements for human bodies.
The term "beta-casein" is a phosphorylated protein synthesized by mammary acinar epithelial cells and is widely found in the milk of mammals (cows, yaks, goats, horses, rabbits, etc.) and humans.
The term "OPO structure fat" is actually a structured fat, and the molecular structure of breast milk fat is simulated by an enzymatic lipid exchange technology, so that the proportion of 2-position palmitic acid is up to more than 40 percent and is closer to the level of breast milk.
The invention has the following beneficial effects:
the dairy product according to the invention improves or promotes the growth of the body length of infants or young children.
Detailed Description
Embodiments of the present invention will now be described more fully hereinafter with reference to the accompanying examples, in which some, but not all embodiments of the invention are shown. The following description of at least one exemplary embodiment is merely illustrative in nature and is in no way intended to limit the invention, its application, or uses. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
(1) According to the formula in the table 1-1, whole milk powder, skimmed milk powder, lactose, whey protein powder (with a purity of 80 wt.%), desalted whey powder (with a purity of 12 wt.%), a-whey protein powder (with a purity of 77 wt.%), OPO structure fat, high-oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (with a purity of 57 wt.%), fructo-oligosaccharide (from chicory), beta-casein, soya lecithin, choline chloride and compound nutrients (the components are shown in the table 1-2) are uniformly mixed, and impurities are removed by a filter screen of a mixed material to obtain an impurity-removed material;
(2) Homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) Concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) Sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) Preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) Further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) Dry mixing the dry powder, DHA, ARA and two kinds of bifidobacterium powder at 25-30 ℃ through a secondary fluidized bed to obtain mixed powder;
(8) And (3) sieving the mixed powder through a vibrating screen to obtain formula milk powder 1 with uniform particles, and filling nitrogen for packaging.
In the formula 1, the palmitic acid glyceride contains 22% of Sn-2 palmitic acid glyceride, the weight ratio of a-lactalbumin, beta-casein and Sn-2 palmitic acid glyceride is 2.4, the formula contains 1.6wt.% of a-lactalbumin, and the sum of the viable count of two bifidobacteria is 2 multiplied by 10 according to the gram of a-lactalbumin 7 CFU。
Table 1-1 formulation of example 1
Figure BDA0002387976320000111
Figure BDA0002387976320000121
Table 1-2 ingredients contained in the Complex Nutrients
Figure BDA0002387976320000122
Figure BDA0002387976320000131
Example 2
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 34 wt.%), desalted whey powder (purity 12 wt.%), a-whey protein powder (purity 77 wt.%), OPO structure fat, high-oleic sunflower seed oil, corn oil, soybean oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo-oligosaccharide (chicory source), beta-casein, soybean phospholipid, choline chloride and compound nutrients (the components are shown in Table 2-2) uniformly according to the formula in Table 2-1, and removing impurities from the mixed material by using a filter screen to obtain a material after impurity removal;
(2) Homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) Concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) Sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) Preheating the sterilization material in the concentrated milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) Further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) Dry mixing the dry powder, DHA, ARA and two kinds of bifidobacterium powder at 25-30 ℃ through a secondary fluidized bed to obtain mixed powder;
(8) And (3) sieving the mixed powder by using a vibrating screen to obtain the formula milk powder 2 with uniform particles, and filling nitrogen for packaging.
In the formula 2, the palmitic acid glyceride contains 22% of Sn-2 palmitic acid glyceride, the weight ratio of a-lactalbumin, beta-casein and Sn-2 palmitic acid glyceride is 2.5 7 CFU。
Table 2-1 formulation of example 2
Figure BDA0002387976320000141
Figure BDA0002387976320000151
TABLE 2-2 ingredients contained in the Complex Nutrients
Figure BDA0002387976320000152
Figure BDA0002387976320000161
Comparative example
(1) Mixing whole milk powder, skimmed milk powder, lactose, whey protein powder (purity 80 wt.%), desalted whey powder (purity 12 wt.%), OPO structure fat, high oleic sunflower seed oil, corn oil, soybean oil, rapeseed oil, galacto-oligosaccharide syrup (purity 57 wt.%), fructo oligosaccharide (from chicory), soybean phospholipid, choline chloride and compound nutrients (the components are shown in table 3-2) uniformly according to the formula in table 3-1, and removing impurities by using a mixed material filter screen to obtain an impurity-removed material;
(2) Homogenizing the material after removing impurities at a temperature above 55 deg.C under 120bar to obtain homogenized material, and cooling to below 20 deg.C;
(3) Concentrating the standby materials to obtain a concentrate with the dry matter content of 48-52%;
(4) Sterilizing the concentrate at above 83 deg.C for 25 s to obtain sterilized material, and temporarily storing in a concentrated milk balance tank;
(5) Preheating the sterilized material in a thick milk balance tank to 60-70 ℃ by a scraper preheater, filtering by a filter with the aperture of 1mm, pumping into a drying tower by a high-pressure pump for spray drying, wherein the air inlet temperature is 165-180 ℃, the air exhaust temperature is 83-96 ℃, the pressure of the high-pressure pump is 160-210 bar, and the negative pressure of the tower is about-5 mmWG, so as to obtain powder;
(6) Further drying the powder material by a first-stage fluidized bed to obtain dry powder;
(7) Dry mixing the dry powder, DHA and ARA at 25-30 ℃ by a secondary fluidized bed to obtain mixed powder;
(8) And (3) sieving the mixed powder by using a vibrating screen to obtain formula milk powder A with uniform particles, and filling nitrogen for packaging.
In formula A, the palmitic acid glyceride contains 12.5% by weight of Sn-2 palmitic acid glyceride, and is substantially free of a-lactalbumin, beta-casein, and bifidobacteria.
TABLE 3-1 formulation of comparative example
Components Dosage (kg)
Whole milk powder 230
Defatted milk powder 100
Lactose 305
Whey protein powder (purity 80 wt.%) 50
Desalted whey powder (12 wt.% pure) 170
OPO structural fat 100
High oleic sunflower oil 40
Corn oil 30
Soybean oil 70
Rapeseed oil 60
Galactooligosaccharide syrup (purity 57 wt.%) and 45
fructo-oligosaccharide (chicory source) 10
Soybean lecithin 1.4
Choline chloride 0.9
DHA 6
ARA 6
Compound nutrient 13.4
TABLE 3-2 ingredients contained in the Complex Nutrients
Figure BDA0002387976320000171
Figure BDA0002387976320000181
Clinical test method and test results
The feeding effect of the formula of example 1 was compared to the formula of the comparative example by a random control design.
1. Grouping of subjects:
infants in need of inclusion were screened by recruiting screening questionnaires by pediatricians or trained researchers. Written informed consent was obtained from the mother prior to study entry.
1.1 inclusion criteria
And (3) full-term infants: the gestational week is more than or equal to 37 weeks;
birth weight: 2.5kg-4kg;
normal pregnancy, delivered baby (including cesarean);
healthy, apgar score > 7 after birth for 5-10 minutes;
age: < 15 days.
1.2 exclusion criteria
Infants with any of the following characteristics were excluded:
congenital malformations or chromosomal disorders detected at birth and of clinical significance;
patients with disease requiring mechanical ventilation or medication within one week after birth (infant jaundice patients who do not include blue light therapy);
those who affect feeding or metabolism due to suspected or unknown metabolic factors or due to physical defects;
twins or multiple births.
1.3 Experimental groups
Infants of 0-6 months old and full-term are selected as study objects, the infants are fed with the infant formula milk powder, the feeding amount of the infant formula milk powder of 1-15 days old is more than or equal to 250ml/d, the infants with the dry starting prognosis milk powder feeding rate of more than 80% are randomly divided into a test group (fed with the formula milk powder of example 1) and a control group (fed with the formula milk powder of a comparative example). The number of people in each group is not less than 5.
2. Intervention study method
Baseline (postnatal day 15) surveys and sample collections were conducted on the enrolled infants for 6 months of continuous feeding during which the subjects were followed by the project investigator at 4, 6, 8, 16, and 24 weeks after the start of feeding. And (5) investigating the growth and development conditions of the infants.
3. Results of clinical experiments
The Z scoring method is the most common method for evaluating the nutritional status of the group of children before school age at present, and because the influences of factors such as age, sex, height and the like are eliminated, the evaluation result is more accurate and objective. The weight and the height are selected as two evaluation indexes, the numerical value of the standard reference population adopts the international standard or WHO standard designated by the national health statistic center (NCHS), and the Z score of the age-related Height (HAZ) of each child is calculated respectively. The Z score is calculated using the standard formula: z-score = (measured-median standard reference population)/standard deviation of standard reference population. The Z score of HAZ is less than 2, and is regarded as the basis for judging low weight, hypoevolutism and emaciation of children, and the Z score of HAZ is more than 2, and is regarded as overweight, overweight and obese.
The Z-scores of the age Height (HAZ) at baseline, week 4, week 6, week 8, week 16 and week 24 for the infants in the test and control groups are shown in table 4. Where each data is represented in the median (25 th percentile, 75 th percentile). The Z-scores for each group of infants are ranked from low to high, "median" represents the Z-score for infants ranked in the middle position, "25 th percentile" represents the Z-score for infants ranked in (cohort × 25%) position, and "75 th percentile" represents the Z-score for infants ranked in (cohort × 75%) position. The p-value represents the p-value of the significance test between the control and test groups.
Pure artificial feeding means that the feeding amount of the artificial milk powder exceeds 80 percent of the daily food intake.
TABLE 4Z score (middle (25 th percentile, 75 th percentile) for pure artificially fed infant age Height (HAZ)
Test group Control group
HAZ 0.2(-0.78,1.18) -0.2(-0.91,0.62)
p value 0.027
From the above results, it can be seen that the infants in the test group and the control group had a significant difference in the growth of their body length (α =0.05 level) under the pure artificial feeding condition, and the infants in the test group had a significantly faster growth of their body length than those in the control group. This demonstrates that the present formula improves or promotes the growth of the length of the infant.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims (25)

1. Use of a dairy product for the manufacture of a food product or medicament for improving or promoting growth in the body length of a mammal or a human;
the dairy product comprises: a protein providing material, a fat providing material and bifidobacteria; wherein,
the raw material for providing protein is selected from animal milk, milk powder, whey protein powder and beta-casein, and the raw material for providing protein at least contains alpha-whey protein and beta-casein;
the raw material for providing fat at least contains palmitic acid glyceride, and the palmitic acid glyceride contains 30% by weight or more of Sn-2 palmitic acid glyceride;
the Bifidobacterium is Bifidobacterium BB12 and Bifidobacterium HN019;
wherein, among the dairy products, its characterized in that:
the weight ratio of the alpha-lactalbumin to the beta-casein to the Sn-2 glyceryl palmitate is (1-10) to (1-10);
the viable count of the bifidobacteria is 10 according to the weight of beta-casein per gram 6 ～10 11 CFU；
Wherein the ratio of viable count of bifidobacterium BB12 to bifidobacterium HN019 is (1.
2. The use according to claim 1, wherein the protein-providing material is 200 to 1600 parts by weight and the fat-providing material is 70 to 500 parts by weight.
3. Use according to claim 1 or 2, wherein in the dairy product the fat providing raw material is selected from the group consisting of OPO structural fats, vegetable fats and oils and animal fats and oils.
4. Use according to claim 3, wherein the vegetable oil is selected from sunflower oil, corn oil, rapeseed oil and soybean oil.
5. Use according to claim 1 or 2, wherein the dairy product further comprises a carbohydrate providing raw material.
6. Use according to claim 5, wherein the carbohydrate-providing raw material is selected from lactose, sucrose, glucose, starch and dextrin.
7. Use according to claim 5, wherein the carbohydrate-providing raw material is 100 to 600 parts by weight.
8. Use according to claim 1, wherein the dairy product further comprises at least one selected from the group consisting of vitamins, minerals, dietary fiber, DHA, ARA, phospholipids and choline chloride.
9. Use according to claim 1, wherein the dairy product comprises:
Figure QLYQS_1
and the dairy product comprises Bifidobacterium BB12 and Bifidobacterium HN019, wherein the viable count of the bifidobacterium BB12 is 10 according to the weight of beta-casein per gram 6 ～10 11 The viable count of CFU and bifidobacterium HN019 is 10 in terms of per gram of beta-casein 6 ～10 11 CFU。
10. Use according to claim 9, wherein the milk product further comprises vitamins and/or minerals.
11. Use according to claim 10, wherein the vitamin is present in an amount of 1 to 500mg per hundred grams of dairy product.
12. Use according to claim 10, wherein the mineral is present in an amount of 10 to 3000mg per hundred grams of milk product.
13. Use according to any one of claims 8 to 12, wherein the dairy product is characterized by one or more of the following (a) to (d):
(a) The animal milk and milk powder are respectively derived from at least one mammal selected from cow, sheep, horse, deer and camel;
(b) The lactalbumin powder is selected from desalted lactalbumin powder, undesalted lactalbumin powder and alpha-lactalbumin powder;
(c) The dietary fiber is selected from fructo-oligosaccharide and galacto-oligosaccharide;
(d) The phospholipid is soybean phospholipid.
14. The use according to claim 13, wherein in item (b), the weight of the desalted whey protein powder is 1 to 20 times of the weight of the undesalted whey protein powder.
15. The use according to claim 13, wherein in item (b), the weight of the undesalted whey protein powder is 0.5-40 times of the weight of the alpha-whey protein powder.
16. The use of claim 13, wherein the weight ratio of fructo-oligosaccharide to galacto-oligosaccharide in item (c) is 1 (1-6).
17. Use according to any one of claims 9 to 12, wherein the dairy product is prepared by:
(1-1) mixing the raw materials except for bifidobacterium, DHA and ARA to obtain a mixture;
(2-1) homogenizing the mixture to obtain a homogeneous material;
(3) Sterilizing the homogenized material to obtain a sterilized material;
(4) Drying the sterilized material to obtain powder;
(5) And dry-mixing the powder, the bifidobacterium, the DHA and the ARA to obtain the dairy product.
18. Use according to claim 17, characterized by one or more of the following 1) to 11):
1) The method also comprises a step (1-2) between the steps (1-1) and (2-1): filtering the mixture to remove impurities, and using the obtained filtered material for homogenization treatment in the step (2-1);
2) In the step (2-1), the temperature of the homogenization treatment is 50 ℃ or higher;
3) In the step (2-1), the pressure of the homogenization treatment is 120bar or more;
4) The method also comprises a step (2-2) between the steps (2-1) and (3): concentrating the homogenized material, and using the obtained concentrate for sterilization treatment in the step (3);
5) In the step (3), the temperature of the sterilization treatment is more than 80 ℃;
6) In the step (3), the time of sterilization treatment is 10-60 seconds;
7) In the step (4), before drying treatment, filtering and removing impurities from the sterilized material;
8) In the step (4), the sterilized material is firstly introduced into a spray drying tower for primary drying, and then the material obtained by the primary drying is introduced into a fluidized bed for secondary drying to obtain powder;
9) In the step (5), the dry mixing temperature is 20-35 ℃;
10 In step (5), dry mixing is carried out by means of a fluidized bed;
11 The method further comprises step (6): the dairy product is screened.
19. Use according to claim 18, wherein in item 4), the dry matter content of the concentrate in step (2-2) is between 40% and 60% by weight.
20. The use according to claim 18, wherein, in the step (4), the temperature of the inlet air of the spray drying tower is 150-200 ℃.
21. The use according to claim 18, wherein in item 8), the temperature of the air discharge of the spray drying tower in step (4) is 80 ℃ to 120 ℃.
22. The use according to claim 18, wherein, in the step (4), the negative pressure of the spray drying tower is-10 to-2 mmWG in the 8).
23. The use according to claim 18, wherein in item (8), the sterilizing material is introduced into the spray-drying tower in step (4) by means of a high-pressure pump.
24. The use according to claim 23, wherein, in item 8), the pressure of the high-pressure pump in step (4) is 140 to 250bar.
25. The use according to claim 1, wherein the human is an infant or a juvenile.
CN202010104314.1A 2019-11-20 2020-02-20 Application of dairy product in promoting growth of length of mammal Active CN111227045B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019111427130 2019-11-20
CN201911142713 2019-11-20

Publications (2)

Publication Number Publication Date
CN111227045A CN111227045A (en) 2020-06-05
CN111227045B true CN111227045B (en) 2023-04-14

Family

ID=70862730

Family Applications (8)

Application Number Title Priority Date Filing Date
CN201911345399.6A Pending CN112823646A (en) 2019-11-20 2019-12-24 Composition, food or drug and use thereof
CN202010104302.9A Active CN111248287B (en) 2019-11-20 2020-02-20 Application of dairy product in improving neurodevelopment
CN202010104301.4A Active CN111227044B (en) 2019-11-20 2020-02-20 Dairy product, preparation method and medical application thereof
CN202010104314.1A Active CN111227045B (en) 2019-11-20 2020-02-20 Application of dairy product in promoting growth of length of mammal
CN202010135335.XA Active CN112823647B (en) 2019-11-20 2020-03-02 Application of composition in improving or promoting growth of infant
CN202010135666.3A Active CN112823667B (en) 2019-11-20 2020-03-02 Application of the composition in preventing or alleviating colic in infants and young children
CN202310545216.5A Withdrawn CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202010135640.9A Active CN112823648B (en) 2019-11-20 2020-03-02 Composition, food or medicine and application thereof

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201911345399.6A Pending CN112823646A (en) 2019-11-20 2019-12-24 Composition, food or drug and use thereof
CN202010104302.9A Active CN111248287B (en) 2019-11-20 2020-02-20 Application of dairy product in improving neurodevelopment
CN202010104301.4A Active CN111227044B (en) 2019-11-20 2020-02-20 Dairy product, preparation method and medical application thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN202010135335.XA Active CN112823647B (en) 2019-11-20 2020-03-02 Application of composition in improving or promoting growth of infant
CN202010135666.3A Active CN112823667B (en) 2019-11-20 2020-03-02 Application of the composition in preventing or alleviating colic in infants and young children
CN202310545216.5A Withdrawn CN116584653A (en) 2019-11-20 2020-03-02 Application of composition in preventing or relieving infant colic
CN202010135640.9A Active CN112823648B (en) 2019-11-20 2020-03-02 Composition, food or medicine and application thereof

Country Status (1)

Country Link
CN (8) CN112823646A (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823646A (en) * 2019-11-20 2021-05-21 内蒙古伊利实业集团股份有限公司 Composition, food or drug and use thereof
CN114223721A (en) * 2020-09-09 2022-03-25 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in improving or promoting protein absorption of infants
CN116998725B (en) * 2020-11-30 2025-09-16 内蒙古伊利实业集团股份有限公司 Composition containing fructo-oligosaccharide and probiotics and application thereof
CN114287478A (en) * 2021-11-23 2022-04-08 临夏燎原乳业产业研究院有限公司 Formula yak milk powder for promoting height increase and brain development of children and preparation method thereof
CN114145458A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body
CN114145346A (en) * 2021-11-29 2022-03-08 内蒙古伊利实业集团股份有限公司 Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder
CN115669945B (en) * 2022-10-24 2024-03-08 上海艾斯顿医疗科技有限公司 Liposome-coated polypeptide with neurotrophic effect, and preparation method and application thereof
CN115825294B (en) * 2023-02-07 2023-05-26 北京三元食品股份有限公司 Marker group for evaluating infant communication capacity and development condition and application thereof
CN116008438B (en) * 2023-02-07 2023-06-06 北京三元食品股份有限公司 Marker group for evaluating fine action development condition of infants and application
CN116369527B (en) * 2023-03-09 2024-07-30 江南大学 Bifidobacterium breve capable of regulating bone development and application thereof
CN118717809A (en) * 2023-03-24 2024-10-01 丰华生物科技股份有限公司 Use of culture of Bifidobacterium longum subsp. infantis BLI-02 in improving calcium absorption

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012335224B2 (en) * 2011-11-10 2016-10-13 Société des Produits Nestlé S.A. Infant formula with high sn-2 palmitate and oligofructose
CN102524421B (en) * 2011-12-31 2013-05-22 黑龙江省完达山乳业股份有限公司 Novel acid-base balance infant formula milk powder and preparation method thereof
MX2012010488A (en) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Infant formula for optimal growth, gastrointestinal protection and immunological protection of infants.
MX2012010487A (en) * 2012-09-11 2014-03-26 Nucitec Sa De Cv Composition of nutrients and bioactive substances which promote growth and reduce intolerance and side effects in premature infants.
CN103053694A (en) * 2013-02-18 2013-04-24 杨凌圣妃乳业有限公司 Infant goat milk powder simulating components of breast milk and preparation method thereof
FR3005392B1 (en) * 2013-05-07 2015-09-18 United Pharmaceuticals ANTI-REGURGITATION COMPOSITION PRESERVING INTESTINAL TRANSIT
CN104351356A (en) * 2014-11-25 2015-02-18 澳优乳业（中国）有限公司 Novel fourth-generation infant formula and preparation method thereof
CN105767213A (en) * 2014-12-26 2016-07-20 丰益(上海)生物技术研发中心有限公司 Grease composition and preparation method thereof
CN106259953B (en) * 2015-06-01 2019-01-29 内蒙古伊利实业集团股份有限公司 Breast milk 0-12 month babies ' formula milk powder containing nucleotide and preparation method thereof
CN106259952B (en) * 2015-06-01 2019-01-15 内蒙古伊利实业集团股份有限公司 1-3 years old baby formulas milk powder and preparation method thereof containing nucleotide and dietary fiber
CN105053217A (en) * 2015-09-14 2015-11-18 海普诺凯营养品有限公司 Infant formula ewe milk powder and production method thereof
CN107439686A (en) * 2016-05-31 2017-12-08 内蒙古伊利实业集团股份有限公司 A kind of full-cream chocolate milk and preparation method thereof
CN107668211B (en) * 2017-11-13 2021-08-10 海普诺凯营养品有限公司 Infant formula goat milk powder for enhancing immune function and preparation method thereof
WO2019104390A1 (en) * 2017-12-01 2019-06-06 Freedom Foods Group IP Pty Limited Milk substitute compositions
CN110063372A (en) * 2018-01-23 2019-07-30 天津澳斯乳业有限公司 A kind of infant formula goat milk powder and its production method
CN108013143A (en) * 2018-02-05 2018-05-11 高培（广州）乳业有限公司 A formula milk powder for strengthening the gastrointestinal function of infants aged 12 to 36 months
CN108157512A (en) * 2018-02-05 2018-06-15 高培（广州）乳业有限公司 A formula milk powder for strengthening the gastrointestinal function of infants aged 6-12 months
CN112823646A (en) * 2019-11-20 2021-05-21 内蒙古伊利实业集团股份有限公司 Composition, food or drug and use thereof

Also Published As

Publication number Publication date
CN112823647B (en) 2023-04-07
CN116584653A (en) 2023-08-15
CN112823648B (en) 2023-03-31
CN111227044A (en) 2020-06-05
CN112823667B (en) 2023-06-02
CN111248287A (en) 2020-06-09
CN111227045A (en) 2020-06-05
CN112823647A (en) 2021-05-21
CN112823667A (en) 2021-05-21
CN111227044B (en) 2023-05-16
CN112823646A (en) 2021-05-21
CN111248287B (en) 2023-04-14
CN112823648A (en) 2021-05-21

Similar Documents

Publication Publication Date Title
CN111227045B (en) Application of dairy product in promoting growth of length of mammal
CN1838888B (en) Baby or second stage formula milk
US9591872B2 (en) Nutritional composition for children with reflux, colic and/or constipation
CN101299934B (en) Nutritional formulation for promoting catch-up growth
TW201028104A (en) Nutritional composition to promote healthy development and growth
HK1252651A1 (en) Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid
CN114145346A (en) Food composition, application of food composition in improving or promoting magnesium absorption and infant formula milk powder
EP1803358A1 (en) Infant immunological formula
JP2016505024A (en) Baby food composition containing bacteria that produce viable propionic acid
JP2016505024A5 (en)
JP2024508402A (en) Compositions and methods using a combination of oleuropein and vitamin B6
MX2013005943A (en) Use of nutritional compositions including lactoferrin in supporting resistance to diseases and conditions.
EA011075B1 (en) Dry powdered milk formula
CN112535217A (en) Maternal emulsified hypoallergenic fresh and alive infant formula milk and preparation method thereof
ES2857815T3 (en) Methods of use of fermented formula for infants
JP2024507502A (en) Compositions and methods using combinations of oleuropein and magnesium
JP2025063271A (en) Food grade butyrate and its uses
CN114223721A (en) Application of palmitic acid glyceride in improving or promoting protein absorption of infants
Falcão et al. Infant Formulas: a long story
CN114145458A (en) Application of palmitic acid glyceride in preparing composition for improving or promoting magnesium absorption of human body
CN111227046B (en) Application of dairy product in improving infant intestinal SIgA level
CN117580465A (en) Nutritional composition for human consumption and method for preparing the same
JPH10262607A (en) Nutrient composition for infant
TW201822640A (en) a composition comprising maltotriose and a method of using the same to inhibit damage caused by a dehydration method
US12527342B2 (en) Supplementary composition containing 2′-fucosyllactose (2′-fl) and fructo-oligosaccharide (FOS) with synergistic effects on the digestive and immune systems for children, and process of manufacturing a children formula containing said supplementary composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant